Navigation Links
MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
Date:2/28/2008

VALENCIA, Calif., Feb. 28 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2007 fourth quarter financial results on Tuesday, March 4, 2008 at 7:00 a.m. ET.

Management of the Company will host a conference call to discuss the fourth quarter financial results, clinical progress and other Company developments at 9:00 a.m. ET on Tuesday, March 4, 2008. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Dick Anderson and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 566-5775 or (210) 234-0004. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (866) 396-7637 or (203) 369-0522. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. MannKind to Present at the Wachovia 2008 Healthcare Conference
3. MannKind to Present at the Piper Jaffray Healthcare Conference
4. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
5. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
6. MannKind to Present at the UBS Global Life Sciences Conference
7. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
8. Insulet Corporation to Report Fourth Quarter and Full Year 2007 Financial Results on Monday, March 17
9. Pharmion Corporation Announces 2007 Operating Results
10. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
11. VLST Corporation Announces Board and Executive Management Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Oregon (PRWEB) , ... December 08, 2016 , ... ... and the FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI ... not require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. ... bioprocess media products engineered to radically streamline culture processes, minimize processing time, ...
(Date:12/8/2016)... 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a ... plans to commercialize innovative therapeutics for patients with ... were approved for trading on the OTCQX U.S. ... OTCQX, effective today, under the ticker symbol "HPPI." ... companies must meet high financial standards, follow best ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented today ... clinical trial for its lead drug candidate, AC0010, at the World Conference on ... to determine the safety, antitumor activity, and recommended phase II dosage of AC0010 ...
Breaking Biology Technology:
(Date:12/7/2016)... According to a new market research report "Emotion Detection ... Voice Recognition), Service, Application Area, End User, And Region - Global Forecast to ... 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a Compound ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
Breaking Biology News(10 mins):